SCHEMBL6286174

SCHEMBL6286174

CS(=O)(=O)c1cccc(N)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.46
GAA P10253 1/20 0.45
MMP2 P08253 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CYP2C9 P11712 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
ACLY P53396 1/20 0.41
NSD2 O96028 2/20 0.40
HTR6 P50406 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CDK2 P24941 1/20 0.38
GLO1 Q04760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527264 0.84 ENPP2 (0.42) TTRMMP2CA1CA2CA6
SCHEMBL564728 0.83 GAA (0.60) TTRGAAMMP2CA12CA1
SCHEMBL17871618 0.81 TTR (0.41) TTRGAAMMP2CA12CA1
SCHEMBL3030725 0.81 TTR (0.62) TTRGAAMMP2CA12CA1
SCHEMBL1121320 0.81 CA1 (0.61) TTRGAAMMP2CA12CA1
SCHEMBL8023642 0.80 ACLY (0.49) TTRGAAMMP2CA12CA1
SCHEMBL20760437 0.79 TTR (0.46) TTRGAAMMP2CA12CA1
SCHEMBL12086969 0.79 ALDH1A1 (0.45) TTRGAAMMP2CA12CA1
SCHEMBL1110597 0.78 GAA (0.48) TTRGAACA12CA1CA2
SCHEMBL6828498 0.78 CDK2 (0.48) GAAMMP2CA1CA2CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414442-B 1H- pyrrolo- [2,3-c] pyridine -7 (6H) -one and pyrazolo [3,4-c] pyridine -7 (6H) -one as BET protein inhibitor 因赛特公司 2019-03-15 CN disclosed
US-6969711-B2 Cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2005-11-29 US disclosed
EP-0987254-B1 NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME KOWA CO (JP) 2004-12-22 EP disclosed
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2004-02-26 US disclosed
EP-0987254-A1 NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same LCAT, ACAT2, ACAT1 TTR 1801/4885GAA 988/4885MMP2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.